Category: Latest News

The Multiple Sclerosis Association of America (MSAA) in partnership with @Point of Care, is proud to announce a new video series titled “Understanding Multiple Sclerosis.” This 12-part video series, featuring expert neurologist Dr. Michelle Fabian, provides an overview of the MS process, possible causes, symptoms, treatments, wellness strategies, and more. Each video offers valuable insights and up-to-date information in a relaxed, conversational style that is easy to understand and follow.

Started in 2009, the MSAA Art Showcases are comprised of two categories: the MS Ability Art Showcase and the Four Seasons Art Showcase. Artists with a diagnosis of MS are invited each fall to submit their best oil, watercolor, acrylic or pastel paintings, as well as drawings in ink or pencil. The artwork debuts on MSAA’s website, alongside the artists’ personal stories during MS Awareness Month every March.

In a news release dated March 29, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mavenclad® (cladribine) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval is for individuals with relapsing-remitting MS (RRMS) and for individuals with active secondary-progressive MS (SPMS).

In a news release dated March …

The opening months of 2019 saw significant research advances on many fronts in multiple sclerosis (MS). A sophisticated analysis of data using healthcare claims found that the number of people in the United States living with MS is more than twice as high as previously estimated. Dietary studies sounded a cautionary note for people with MS drinking soda and many other sweetened beverages, and a hopeful note on the potential for flavonoid-rich cocoa to reduce MS-associated fatigue. A promising stem-cell therapy is moving forward in the clinical-trials process, while the FDA is considering whether to approve a new disease-modifying therapy (DMT).

The Multiple Sclerosis Associa …

The Multiple Sclerosis Associa …

This installment of “What’s New in MS Research” highlights the breadth of that research, as the nine studies reported below examine everything from a possible link between food allergies and MS disease activity, to the promise of stem cell transplantation in people who have not obtained a satisfactory response from multiple disease-modifying therapies (DMTs). Important studies on the potential causes of MS, the role of patient preferences in drug selection and adherence, and other topics also are covered.

This year’s gathering was held in Berlin, Germany, October 10-12, where the findings were presented from hundreds of studies on topics ranging from the safety and effectiveness of investigational medications to the role of diet in controlling symptoms of MS.

Research into the causes, diagnosis, impact, and management of multiple sclerosis (MS) continues to move forward on a broad front and at a rapid pace. While many advances are announced at medical meetings, such as the annual gatherings of the American Academy of Neurology (AAN), American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Consortium of Multiple Sclerosis Centers (CMSC), and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), other findings are reported in medical journals throughout the year.